• First full year of Nasodine Nasal Spray sales globally
• Promising sales growth in US, Singapore and Fiji markets
• Expansion into the Philippines and other Southeast Asian markets planned for FY2026
• New Nasodine products to be launched in FY2026

Firebrick Pharma Ltd reported its FY2025 results, which was the first full year of sales for its Nasodine Nasal Spray product globally. The company saw promising sales growth in its initial markets of the US, Singapore and Fiji. In the US, Firebrick successfully launched Nasodine online in April 2024 and is now planning initiatives including new packaging, a new website and a push for retail distribution in FY2026. In Singapore, Firebrick started with online sales in June 2024 and then moved into healthcare professional promotion and retail distribution through the Guardian pharmacy chain. A key achievement was the adoption of Nasodine in all government hospitals and pharmacies operated by the National Healthcare Group. Firebrick also signed a licensing and distribution agreement for Nasodine in Fiji and the South Pacific with Makans Limited. While these initial markets are still relatively small, the company sees them as important for building international awareness and sales momentum for Nasodine. Looking ahead, Firebrick expects to see Nasodine approved or launched in more Southeast Asian markets in FY2026, including the Philippines where it has a strong partner in SV More Pharma. The company also plans to introduce one or more new Nasodine products in FY2026 to further expand the sales potential and build the Nasodine brand franchise. Overall, Firebrick's first full year of Nasodine sales has been a success, and the company is well-positioned for further growth and expansion in the year ahead.

Firebrick Pharma expects to see Nasodine approved or launched in more Southeast Asian markets, including the Philippines, in the 2026 financial year. The company also plans to introduce one or more new Nasodine products in the 2026 financial year.

Firebrick Pharma is well-positioned for further growth and expansion of its Nasodine product in the 2026 financial year, with plans for new market entries, new product launches, and initiatives to drive sales in its initial markets of the US, Singapore and Fiji.